• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
PARP inhibitor combinations in prostate cancer.前列腺癌中的PARP抑制剂联合疗法
Ther Adv Med Oncol. 2020 Mar 18;12:1758835919897537. doi: 10.1177/1758835919897537. eCollection 2020.
2
PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.前列腺癌中的聚 ADP 核糖聚合酶抑制剂：临床前原理与当前临床开发。
Genes (Basel). 2019 Jul 26;10(8):565. doi: 10.3390/genes10080565.
3
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.聚（ADP-核糖）聚合酶（PARP）抑制剂联合策略治疗卵巢癌：文献综述
Diagnostics (Basel). 2019 Aug 1;9(3):87. doi: 10.3390/diagnostics9030087.
4
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.PARP 抑制剂在转移性前列腺癌中的新兴作用。
Curr Oncol Rep. 2022 Nov;24(11):1619-1631. doi: 10.1007/s11912-022-01305-0. Epub 2022 Aug 6.
5
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.PARP 抑制剂在乳腺癌中的应用：将合成致死性带入临床实践。
Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
6
Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.聚腺苷二磷酸核糖聚合酶抑制剂：肿瘤放射治疗增敏中的进展、意义及挑战
Front Oncol. 2023 Dec 4;13:1295579. doi: 10.3389/fonc.2023.1295579. eCollection 2023.
7
PARP inhibitors and more.聚（ADP-核糖）聚合酶抑制剂及其他。
J Turk Ger Gynecol Assoc. 2015 Jun 1;16(2):107-10. doi: 10.5152/jtgga.2015.15029. eCollection 2015.
8
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.针对癌症治疗的 DNA 修复：PARP 抑制剂试验的经验教训。
Oncol Res. 2023 Jun 27;31(4):405-421. doi: 10.32604/or.2023.028310. eCollection 2023.
9
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.同源重组修复和PARP抑制剂在泌尿生殖系统恶性肿瘤中的新作用
Cancer. 2017 Jun 1;123(11):1912-1924. doi: 10.1002/cncr.30631. Epub 2017 Mar 21.
10
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.聚腺苷二磷酸核糖聚合酶抑制剂 veliparib 和组蛋白去乙酰化酶抑制剂 SAHA 协同靶向作用于前列腺癌细胞中的 UHRF1/BRCA1 DNA 损伤修复复合物。
J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.

引用本文的文献

1
Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.解析同源重组修复缺陷型前列腺癌中聚腺苷二磷酸核糖聚合酶抑制剂耐药的分子基础。
Int Rev Cell Mol Biol. 2024;389:257-301. doi: 10.1016/bs.ircmb.2024.03.004. Epub 2024 Mar 31.
2
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.靶向前列腺癌中的白细胞介素-8及其受体：炎症、应激反应与治疗抵抗
Cancers (Basel). 2024 Aug 8;16(16):2797. doi: 10.3390/cancers16162797.
3
To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics.吃还是不吃：关于自噬在前列腺癌发生和前列腺癌治疗中作用的批判性综述。
Front Pharmacol. 2024 Jun 7;15:1419806. doi: 10.3389/fphar.2024.1419806. eCollection 2024.
4
PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development.PARP抑制剂在前列腺癌治疗中的应用：从科学理论依据到临床研发
World J Mens Health. 2024 Apr;42(2):290-303. doi: 10.5534/wjmh.230177. Epub 2023 Sep 14.
5
Altered cytoplasmic and nuclear ADP-ribosylation levels analyzed with an improved ADP-ribose binder are a prognostic factor in renal cell carcinoma.用改良的 ADP-核糖结合物分析的改变的细胞质和核 ADP-核糖基化水平是肾细胞癌的预后因素。
J Pathol Clin Res. 2023 Jul;9(4):273-284. doi: 10.1002/cjp2.320. Epub 2023 Mar 31.
6
Pharmacological Optimization of PSMA-Based Radioligand Therapy.基于前列腺特异性膜抗原（PSMA）的放射性配体疗法的药理学优化
Biomedicines. 2022 Nov 23;10(12):3020. doi: 10.3390/biomedicines10123020.
7
The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems.基于PARP抑制剂的递送纳米系统的当前技术水平
Pharmaceutics. 2022 Aug 8;14(8):1647. doi: 10.3390/pharmaceutics14081647.
8
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.超越 BRCA：DNA 损伤反应与个体化治疗在胰腺癌和前列腺癌患者中的新兴意义。
Int J Mol Sci. 2022 Apr 24;23(9):4709. doi: 10.3390/ijms23094709.
9
A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.一瞥最常见的泌尿生殖系统癌症中新兴的诊断生物标志物。
Saudi J Biol Sci. 2022 Apr;29(4):2072-2084. doi: 10.1016/j.sjbs.2022.01.017. Epub 2022 Jan 15.
10
Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.家族癌症史与前列腺癌主动监测患者的临床和病理结局的关系。
J Urol. 2022 Aug;208(2):325-332. doi: 10.1097/JU.0000000000002668. Epub 2022 Apr 4.

本文引用的文献

1
Exceptional Response to Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects.镥对存在DNA修复缺陷的前列腺癌中前列腺特异性膜抗原的异常反应。
JCO Precis Oncol. 2019 Dec;3:1-5. doi: 10.1200/PO.18.00237.
2
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.西地尼布通过下调 BRCA1/2 和 RAD51 来抑制同源定向 DNA 修复。
Sci Transl Med. 2019 May 15;11(492). doi: 10.1126/scitranslmed.aav4508.
3
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.尼拉帕利激活干扰素信号通路，并增强肿瘤模型中抗 PD-1 抗体的疗效。
Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.
4
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.在一项针对复发性铂类敏感卵巢癌的 Cediranib 和奥拉帕利联合用药与奥拉帕利单药治疗的随机 II 期研究中，总生存期和更新的无进展生存期结果。
Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.
5
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.度伐利尤单抗联合奥拉帕利治疗伴有和不伴有 DNA 损伤修复突变的转移性去势抵抗性前列腺癌男性患者的疗效。
J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.
6
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.聚腺苷二磷酸核糖聚合酶 1（PARP1）捕获剂通过聚腺苷二磷酸核糖聚合酶抑制剂在癌细胞和健康骨髓中引发细胞毒性。
Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14.
7
PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.聚腺苷二磷酸核糖聚合酶抑制诱导 Akt 介导的细胞保护作用，通过形成线粒体靶向磷酸化 ATM-NEMO-Akt-mTOR 信号复合物。
Biochem Pharmacol. 2019 Apr;162:98-108. doi: 10.1016/j.bcp.2018.10.005. Epub 2018 Oct 6.
8
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.镭-223 治疗伴有和不伴有同源修复基因缺陷的骨转移去势抵抗性前列腺癌的疗效。
Eur Urol. 2019 Aug;76(2):170-176. doi: 10.1016/j.eururo.2018.09.040. Epub 2018 Oct 4.
9
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.随机 II 期研究评估 Akt 阻断联合阿比特龙治疗伴有或不伴有 PTEN 缺失的转移性前列腺癌患者的疗效。
Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.
10
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的随机、双盲、安慰剂对照、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.

前列腺癌中的PARP抑制剂联合疗法

PARP inhibitor combinations in prostate cancer.

作者信息

Pezaro Carmel

机构信息

University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield S10 2SJ, UK.

出版信息

Ther Adv Med Oncol. 2020 Mar 18;12:1758835919897537. doi: 10.1177/1758835919897537. eCollection 2020.

DOI:10.1177/1758835919897537
PMID:32215055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7081465/
Abstract

Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that are based on purported synergies in treatment effect. While the initial single-agent development focused on men with identified deficiencies in DNA-repair pathways, broader patient populations are being considered for combination approaches. This review summarizes the current clinical development of PARP inhibitors and explores the rationale for novel combination strategies.

摘要

聚腺苷二磷酸核糖聚合酶（PARP）抑制剂会导致脱氧核糖核酸（DNA）损伤，这对于修复机制存在缺陷的细胞可能是致命的。目前有多种PARP抑制剂正在作为前列腺癌男性患者的治疗方法进行测试，包括单药治疗以及基于所谓协同治疗效果的联合治疗。虽然最初的单药研发聚焦于已确定存在DNA修复途径缺陷的男性患者，但联合治疗方法正在考虑更广泛的患者群体。本综述总结了PARP抑制剂目前的临床研发情况，并探讨了新型联合策略的理论依据。